Patients dropping MS drug Tysabri face relapse risk
Patients dropping MS drug Tysabri face relapse risk
Multiple sclerosis patients treated with natalizumab were more likely to discontinue therapy after learning of a positive JCV antibody result, only to see a higher risk for relapse, according to a small, single-center study reported here.
Of nine patients who discontinued natalizumab (Tysabri) after learning their antibody result, which indicated a heightened risk for progressive multifocal leukoencephalopathy (PML) -- a rare but life-threatening event -- five relapsed within 6 months, said Denise Cheng, RN, of Winthrop Comprehensive MS Care Center in Mineola, N.Y.
These patients may have assumed their MS was no longer active, as opposed to a continuing disease process that was suppressed by the natalizumab treatment, Cheng said at the American Academy of Neurology's annual meeting....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2349 Views
-
Last post by NHE
-
- 0 Replies
- 1383 Views
-
Last post by NHE
-
- 1 Replies
- 949 Views
-
Last post by NHE
-
- 0 Replies
- 2173 Views
-
Last post by NHE
-
- 6 Replies
- 4694 Views
-
Last post by ElliotB
-
- 0 Replies
- 1276 Views
-
Last post by NHE
-
- 0 Replies
- 3243 Views
-
Last post by NHE
-
- 0 Replies
- 1557 Views
-
Last post by NHE
-
- 11 Replies
- 3212 Views
-
Last post by NHE